ASS1 regulates immune microenvironment via CXCL8 signaling in ovarian cancer

Ovarian cancer is one of the most serious and deadly cancers for female and currently no effective screening approaches have been achieved. Therefore it is usually diagnosed at an advanced stage and most patients have a poor prognosis. The development of ovarian cancer is a comprehensive process depending on the cross-talk between the various cells in the tumor microenvironment and the immune system. Thus, the immunotherapy may be revolutionized as an effective treatment of this disease. In this study, we firstly identified ASS1 as an immunomodulatory molecule. By RNA sequencing, antibody array and animal assys, we further provided new insights into understanding the crosstalk between ovarian cancer cells and their microenvironmental immune molecules , which may suggest a new potential therapeutic target for ovarian cancer.(c) 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Automated summary

Ovarian cancer is a serious and deadly disease for females, and effective screening approaches are still lacking. Immunotherapy may revolutionize the treatment of this disease by revealing the interactions between ovarian cancer cells and immune molecules in the microenvironment, potentially leading to new therapeutic targets.